Clinical Trials and Research
Are you interested in enrolling in a retina research clinical trial? Eligible new patients may have the opportunity to participate in studies focused on the diagnosis and treatment of conditions affecting the retina, macula, and vitreous. Clinical research studies are available at our Charleston location, and open to patients from Parkersburg, Beckley, and Huntington locations under the expert care of our dedicated clinical research team.
Explore Clinical Research Opportunities
Last updated on Friday, August 14, 2026
To learn more details about our clinical studies or to inquire about how to participate, please contact us at (304) 346-4400.
Trials Open for Enrollment:
MALBEC
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002 Protocol ID: MK8748-002 (MALBEC)
ClinicalTrials.gov ID: NCT07440225
Sponsor: EyeBiotech Ltd.
This pivotal Phase 2/3 randomized, double-masked, multicenter clinical trial evaluates two dose levels of intravitreal tiespectus, also known as EYE201 or MK-8748, compared with aflibercept in adults with neovascular age-related macular degeneration. Researchers are evaluating whether tiespectus can provide vision outcomes comparable to aflibercept while assessing its safety and durability.
SUPER TUSCAN
A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO (Super Tuscan)
ClinicalTrials.gov ID: NCT07205887
Sponsor: EyeBiotech Ltd.
EYE-RES-104 is a randomized, dose-masked study of intravitreal EYE103 in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO).
HELIOS-3
HELIOS-3: Study of Axitinib Intravitreal Implant in Non-Proliferative Diabetic Retinopathy
ClinicalTrials.gov ID NCT07235085
Sponsor: Ocular Therapeutics
This Phase 3, randomized, masked clinical trial evaluates one or two administrations of an investigational sustained-release axitinib intravitreal implant compared with a sham procedure in adults with moderately severe to severe non-proliferative diabetic retinopathy. Researchers are assessing safety and whether the implant can improve diabetic retinopathy severity and reduce the risk of disease progression.
CLOVER
A decentralized epidemiological study of the progression of Age-related Macular Degeneration (AMD)
Protocol ID: 20190002
Sponsor: Character Bio
The primary objective of the study is to generate a better understanding of the genetic contribution to variability and dynamic range of clinical progression from the earliest stages of drusen formation through to geographic atrophy (GA) and neovascular (nvAMD).
SANGIOVESE
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)
ClinicalTrials.gov ID: NCT07705607
Sponsor: Merck Sharp & Dohme LLC
A Randomized, Double-Masked, Multicenter, 3-Arm, Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) MK-8748 Compared With Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)